Rapidly Growing and Aggressive Cutaneous Squamous Cell Carcinomas in a Patient Treated with Ruxolitinib

Ruxolitinib is a Janus kinase (JAK)1 and JAK2 inhibitor approved for the treatment of myelofibrosis and for polycythemia patients who are resistant or intolerant to hydroxyurea. We report a 72 year-old man patient with polycythemia vera who developed multiple cutaneous squamous cell carcinomas (cSCC...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Ann Dermatol
Asıl Yazarlar: March-Rodriguez, Álvaro, Bellosillo, Beatriz, Álvarez-Larrán, Alberto, Besses, Carles, Pujol, Ramon M, Toll, Agustí
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: The Korean Dermatological Association; The Korean Society for Investigative Dermatology 2019
Konular:
Case Report
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7992689/
https://ncbi.nlm.nih.gov/pubmed/33911570
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5021/ad.2019.31.2.204
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller